Piero Ricchiuto
Research Subjects
Piero Ricchiuto has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Ayan Chatterjee
Alexion AstraZeneca Rare Disease, R&D, Boston, USA
3 shared publications - Babak Ravandi
BioClarity AI Northeastern University Alexion AstraZeneca Rare Disease Northeastern University
3 shared publications - Juan Carlos Mobarec
Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
3 shared publications - Parham Haddadi
Alexion AstraZeneca Rare Disease, R&D, Boston, USA
3 shared publications - William R. Mowrey
Alexion AstraZeneca Rare Disease, R&D, Boston, USA
3 shared publications - Elena Aikawa
Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School , 3 Blackfan Street, 17th Floor, Boston, MA 02115
2 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (16) , 1624-1626
Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials
- 20 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (16) , 1624-1626
Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials
- Open Access
Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases
Evaluating the potential applications of a medicine is a fundamental challenge in drug development. There is a lack of standardized, decision-oriented benchmarks that test whether computational models can generalize therapeutic hypotheses across diseases in ways that reflect real-world pharmaceutical investment decision making. To address this gap, we introduce two complementary resources: the Indication Expansion Investment Decision Network (IxIDN) and the Orphanet Rare Disease Ontology Negative-network (ORDON). IxIDN is a clinical-trial-derived positive benchmark constructed by projecting drug–disease associations from pharmaceutical clinical trials into a disease–disease network; each edge connects disease pairs that have entered clinical trials for the same drug, thereby capturing cases when concrete indication-expansion decisions have been made. The current release contains 574 rare diseases and 5,336 edges. In contrast, ORDON serves as a stringent, biology-aware negative benchmark derived from the authoritative Orphanet Rare Disease Ontology. It identifies maximally distant disease pairs according to curated hierarchical structure and genetics-linked inheritance patterns, providing 793 rare diseases and 5,000 edges that represent high-separation negative candidates across therapeutic areas. Together, IxIDN and ORDON enable rigorous cross-evidence generalization from clinical trials to disease ontology, testing for Disease– Disease Association Learning (DDAL), a core task for mechanism-centered drug repurposing and indication expansion. All data are publicly available with detailed metadata, enabling reproducible evaluation of models on transparent, decision-relevant benchmarks.
Open AccessClinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases
Evaluating the potential applications of a medicine is a fundamental challenge in drug development. There is a lack of standardized, decision-oriented benchmarks that test whether computational models can generalize therapeutic hypotheses across diseases in ways that reflect real-world pharmaceutical investment decision making. To address this gap, we introduce two complementary resources: the Indication Expansion Investment Decision Network (IxIDN) and the Orphanet Rare Disease Ontology Negative-network (ORDON). IxIDN is a clinical-trial-derived positive benchmark constructed by projecting drug–disease associations from pharmaceutical clinical trials into a disease–disease network; each edge connects disease pairs that have entered clinical trials for the same drug, thereby capturing cases when concrete indication-expansion decisions have been made. The current release contains 574 rare diseases and 5,336 edges. In contrast, ORDON serves as a stringent, biology-aware negative benchmark derived from the authoritative Orphanet Rare Disease Ontology. It identifies maximally distant disease pairs according to curated hierarchical structure and genetics-linked inheritance patterns, providing 793 rare diseases and 5,000 edges that represent high-separation negative candidates across therapeutic areas. Together, IxIDN and ORDON enable rigorous cross-evidence generalization from clinical trials to disease ontology, testing for Disease– Disease Association Learning (DDAL), a core task for mechanism-centered drug repurposing and indication expansion. All data are publicly available with detailed metadata, enabling reproducible evaluation of models on transparent, decision-relevant benchmarks.
- Open Access
- 7 April 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (5)
Topology-driven negative sampling enhances generalizability in protein–protein interaction prediction
Motivation: Unraveling the human interactome to uncover disease-specific patterns and discover drug targets hinges on accurate protein–protein interaction (PPI) predictions. However, challenges persist in machine learning (ML) models due to a scarcity of quality hard negative samples, shortcut learning, and limited generalizability to novel proteins. Results: In this study, we introduce a novel approach for strategic sampling of protein–protein noninteractions (PPNIs) by leveraging higher-order network characteristics that capture the inherent complementarity-driven mechanisms of PPIs. Next, we introduce Unsupervised Pre-training of Node Attributes tuned for PPI (UPNA-PPI), a high throughput sequence-to-function ML pipeline, integrating unsupervised pre-training in protein representation learning with Topological PPNI (TPPNI) samples, capable of efficiently screening billions of interactions. By using our TPPNI in training the UPNA-PPI model, we improve PPI prediction generalizability and interpretability, particularly in identifying potential binding sites locations on amino acid sequences, strengthening the prioritization of screening assays and facilitating the transferability of ML predictions across protein families and homodimers. UPNA-PPI establishes the foundation for a fundamental negative sampling methodology in graph machine learning by integrating insights from network topology. Availability and implementation: Code and UPNA-PPI predictions are freely available at https://github.com/alxndgb/UPNA-PPI.
- 7 April 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (5)
Open AccessTopology-driven negative sampling enhances generalizability in protein–protein interaction prediction
Motivation: Unraveling the human interactome to uncover disease-specific patterns and discover drug targets hinges on accurate protein–protein interaction (PPI) predictions. However, challenges persist in machine learning (ML) models due to a scarcity of quality hard negative samples, shortcut learning, and limited generalizability to novel proteins. Results: In this study, we introduce a novel approach for strategic sampling of protein–protein noninteractions (PPNIs) by leveraging higher-order network characteristics that capture the inherent complementarity-driven mechanisms of PPIs. Next, we introduce Unsupervised Pre-training of Node Attributes tuned for PPI (UPNA-PPI), a high throughput sequence-to-function ML pipeline, integrating unsupervised pre-training in protein representation learning with Topological PPNI (TPPNI) samples, capable of efficiently screening billions of interactions. By using our TPPNI in training the UPNA-PPI model, we improve PPI prediction generalizability and interpretability, particularly in identifying potential binding sites locations on amino acid sequences, strengthening the prioritization of screening assays and facilitating the transferability of ML predictions across protein families and homodimers. UPNA-PPI establishes the foundation for a fundamental negative sampling methodology in graph machine learning by integrating insights from network topology. Availability and implementation: Code and UPNA-PPI predictions are freely available at https://github.com/alxndgb/UPNA-PPI.
- Open Access
Representation Learning of Human Diseases for Indication Expansion and Investment Decisions
A fundamental challenge in translational medicine is the computational modeling of complex human diseases to accelerate therapeutic development. Representation learning provides a powerful framework to address this, yet creating models that capture deep biological mechanisms remains a critical need. To this end, we propose a novel strategy that partitions the disease landscape into rare and non-rare categories, enabling systematic knowledge repurposing both within and between these groups. Here, we introduce Dis2Vec (Disease to Vector), a representation learning framework designed to operationalize this concept. Dis2Vec generates biologically grounded disease embeddings by learning from human genetic and phenotypic data, forming the foundation for Disease-Disease Association Learning (DDAL) and unsupervised disease clustering. We evaluate Dis2Vec representations in two downstream applications. First, we assess DDAL performance on a transfer learning benchmark designed to predict therapeutic transferability, using real-world drug repurposing investment decisions made in clinical trials. Second, unsupervised clustering analyses reveal shared biological mechanisms across diseases. By modeling the disease landscape in this way, Dis2Vec enhances translational research efficiency across both rare and non-rare diseases, advancing the development of foundational models for therapeutic science. Furthermore, Dis2Vec establishes a biologically grounded disease-representation and benchmarking layer that paves the way for trustworthy agentic biomedical AI systems in rare-disease indication expansion.
Open AccessRepresentation Learning of Human Diseases for Indication Expansion and Investment Decisions
A fundamental challenge in translational medicine is the computational modeling of complex human diseases to accelerate therapeutic development. Representation learning provides a powerful framework to address this, yet creating models that capture deep biological mechanisms remains a critical need. To this end, we propose a novel strategy that partitions the disease landscape into rare and non-rare categories, enabling systematic knowledge repurposing both within and between these groups. Here, we introduce Dis2Vec (Disease to Vector), a representation learning framework designed to operationalize this concept. Dis2Vec generates biologically grounded disease embeddings by learning from human genetic and phenotypic data, forming the foundation for Disease-Disease Association Learning (DDAL) and unsupervised disease clustering. We evaluate Dis2Vec representations in two downstream applications. First, we assess DDAL performance on a transfer learning benchmark designed to predict therapeutic transferability, using real-world drug repurposing investment decisions made in clinical trials. Second, unsupervised clustering analyses reveal shared biological mechanisms across diseases. By modeling the disease landscape in this way, Dis2Vec enhances translational research efficiency across both rare and non-rare diseases, advancing the development of foundational models for therapeutic science. Furthermore, Dis2Vec establishes a biologically grounded disease-representation and benchmarking layer that paves the way for trustworthy agentic biomedical AI systems in rare-disease indication expansion.
- Open Access
- 31 October 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 12849
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
Despite the global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscure. Here we show, with global proteomic analysis of macrophage cell lines treated with either IFNγ or IL-4, that PARP9 and PARP14 regulate macrophage activation. In primary macrophages, PARP9 and PARP14 have opposing roles in macrophage activation. PARP14 silencing induces pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells, whereas it suppresses anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppresses pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells. PARP14 induces ADP-ribosylation of STAT1, which is suppressed by PARP9. Mutations at these ADP-ribosylation sites lead to increased phosphorylation. Network analysis links PARP9–PARP14 with human coronary artery disease. PARP14 deficiency in haematopoietic cells accelerates the development and inflammatory burden of acute and chronic arterial lesions in mice. These findings suggest that PARP9 and PARP14 cross-regulate macrophage activation.
- 31 October 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 12849
Open AccessPARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
Despite the global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscure. Here we show, with global proteomic analysis of macrophage cell lines treated with either IFNγ or IL-4, that PARP9 and PARP14 regulate macrophage activation. In primary macrophages, PARP9 and PARP14 have opposing roles in macrophage activation. PARP14 silencing induces pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells, whereas it suppresses anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppresses pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells. PARP14 induces ADP-ribosylation of STAT1, which is suppressed by PARP9. Mutations at these ADP-ribosylation sites lead to increased phosphorylation. Network analysis links PARP9–PARP14 with human coronary artery disease. PARP14 deficiency in haematopoietic cells accelerates the development and inflammatory burden of acute and chronic arterial lesions in mice. These findings suggest that PARP9 and PARP14 cross-regulate macrophage activation.
- 1 October 2015
- Published by Elsevier in Journal of Proteomics
- Vol. 128, 132-140
mIMT-visHTS: A novel method for multiplexing isobaric mass tagged datasets with an accompanying visualization high throughput screening tool for protein profiling
- 1 October 2015
- Published by Elsevier in Journal of Proteomics
- Vol. 128, 132-140
mIMT-visHTS: A novel method for multiplexing isobaric mass tagged datasets with an accompanying visualization high throughput screening tool for protein profiling